Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001848278 | SCV002105992 | uncertain significance | Hereditary spastic paraplegia | 2021-10-08 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV002261392 | SCV002540927 | uncertain significance | not provided | 2021-04-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002543381 | SCV003448071 | uncertain significance | Hereditary spastic paraplegia 53 | 2022-11-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt VPS37A protein function. ClinVar contains an entry for this variant (Variation ID: 1344175). This variant has not been reported in the literature in individuals affected with VPS37A-related conditions. This variant is present in population databases (rs201069468, gnomAD 0.05%). This sequence change replaces serine, which is neutral and polar, with arginine, which is basic and polar, at codon 216 of the VPS37A protein (p.Ser216Arg). |
Breakthrough Genomics, |
RCV002261392 | SCV005195818 | uncertain significance | not provided | criteria provided, single submitter | not provided |